Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

Diamantopoulos, Alex; Finckh, Axel; Huizinga, T; Sungher, D K; Sawyer, L; Neto, David; Dejonckheere, F

doi:10.1007/s40273-014-0165-7

Scientific article

English

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

Contributors

Diamantopoulos, Alex; Finckh, Axel

; Huizinga, T; Sungher, D K; Sawyer, L; Neto, David; Dejonckheere, F

Published in

PharmacoEconomics, vol. 32, no. 8, p. 775-787

Publication date

2014

Abstract

Since receiving a positive recommendation in England, Wales and Scotland, tocilizumab (TCZ) is one of the options available to clinicians for the treatment of rheumatoid arthritis (RA) patients in the UK.

UNIGE affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

UNIGE research groups

Inflammation articulaire (44)

Citation (ISO format)

DIAMANTOPOULOS, Alex et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. In: PharmacoEconomics, 2014, vol. 32, n° 8, p. 775–787. doi: 10.1007/s40273-014-0165-7

Article (Published version)

Identifiers

PID : unige:45947
DOI : 10.1007/s40273-014-0165-7
PMID : 24854959

Journal ISSN

1179-2027

546views

543downloads

Creation

27/01/2015 15:35:00

First validation

27/01/2015 15:35:00

Update

24/01/2025 14:34:13

Status update

24/01/2025 14:34:13

Last indexation

24/01/2025 14:42:14

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

Contributors

Published in

Publication date

Abstract

UNIGE affiliation entities

UNIGE research groups

Citation (ISO format)

Main files (1)

Identifiers

Journal ISSN

Technical informations

Creation

First validation

Update

Status update

Last indexation